The healthcare investment thesis I have articulated in this series comes down to one structural filter: does the business work inside the healthcare system that actually exists, not the one that health policy advocates have been hoping for? The system that exists runs on FDA clearance pathways, reimbursement codes, hospital capital budgets, and the specific buying psychology of physicians who do not change procedures without overwhelming evidence. The companies I am watching have all found a way to work within those constraints rather than around them. Each one has a genuine hardware or biological moat, FDA regulatory engagement already underway, and none of them are well known enough to carry an inflated valuation into the conversation.
BiVACOR — Huntington Beach, CA / Houston, TX / Gold Coast, Australia | Founded 2007
What they do: BiVACOR is developing the world’s first magnetically levitated total artificial heart. The BiVACOR TAH is a titanium-constructed biventricular rotary blood pump with a single moving part: a magnetically suspended rotor that simultaneously pumps blood for both the left and right ventricles. No mechanical contact. No moving seals. No potential for mechanical wear. The device is designed for long-term implantation in patients with end-stage biventricular heart failure, either as a bridge to transplant or eventually as destination therapy independent of transplant. The first human implantation was completed on July 9, 2024, at Baylor St. Luke’s Medical Center in Houston. A five-patient FDA Early Feasibility Study is underway, with all five patients successfully bridged to a donor heart transplant. The study is expanding to an additional 15 patients. CTO and inventor Daniel Timms, Ph.D., has spent over two decades on this specific device. The Texas Heart Institute partnership — through William Cohn and O.H. Frazier, two of the world’s most eminent cardiovascular surgeons — provides the clinical infrastructure.
Revenue: Pre-revenue, clinical stage.
Latest raise + backers: $22 million total, comprising a Series B capital raise and an Australian Government Medical Research Future Fund grant of $13 million through the Artificial Heart Frontiers Program consortium led by Monash University. No major U.S. institutional VC involvement. The Australian Government’s MRFF is a non-dilutive funder. The Texas Heart Institute partnership provides clinical infrastructure that smaller companies typically cannot access without much larger capital.
IP: BiVACOR’s MAGLEV blood pump technology is the subject of core patents held by Daniel Timms, Ph.D., covering the magnetic levitation architecture for a biventricular rotary blood pump, the single-rotor design that simultaneously supports both ventricular circuits, and the titanium construction design for long-term biocompatibility. The absence of mechanical contact eliminates the primary failure mechanism of existing ventricular assist devices and the only FDA-approved total artificial heart — SynCardia — which uses 1980s-era pneumatically driven membranes requiring an external air compressor. BiVACOR’s single-moving-part architecture is a structural longevity advantage that SynCardia cannot address without a complete architecture redesign.
Top customers: Texas Heart Institute and Baylor St. Luke’s Medical Center are the primary FDA Early Feasibility Study sites. Monash University, University of New South Wales, University of Queensland, and Griffith University are the Australian consortium partners. St. Vincent’s Hospital Sydney performed the first Australian implantation in November 2024.
Moat and defensibility: The total artificial heart market has one existing product: SynCardia’s TAH, developed in the 1980s using 1980s technology. BiVACOR’s MAGLEV design is not an incremental improvement. It is an architectural replacement. The clinical data being generated in the FDA Early Feasibility Study is the specific type of safety and efficacy evidence that takes years to accumulate and cannot be compressed by capital. Five patients implanted. Five patients successfully bridged to transplant. Study expanding. Daniel Timms has spent over two decades on this specific device. That timeline is not replicable.
SWOT:
| Strengths | Weaknesses |
| First successful human implantation of a MAGLEV total artificial heart. Single moving part eliminates the primary mechanical failure mode of competing devices. All five FDA Early Feasibility Study patients bridged successfully to transplant. Australian Government non-dilutive co-investment. Texas Heart Institute partnership provides world-class cardiac surgery infrastructure. | Clinical stage with no near-term revenue. PMA approval typically requires $300 to $500 million in total development capital — current funding is far below that. Biventricular failure is a smaller initial patient population than left ventricular failure alone. |
| Opportunities | Threats |
| Heart failure is the leading cause of cardiac death worldwide. Fewer than 6,000 annual transplants globally against a patient pool of hundreds of thousands. Destination therapy approval creates a market independent of transplant supply constraints. MAGLEV technology could be adapted for next-generation LVADs in a much larger TAM. | Abbott and Medtronic dominate the VAD market with extensive physician relationships and manufacturing infrastructure. A clinical adverse event in the expansion cohort could delay the Pivotal Trial. PMA timeline is 8 to 12 years from first human use. |
Regulatory and compliance hurdles: BiVACOR is pursuing a Premarket Approval pathway, which requires a full Pivotal Trial demonstrating safety and efficacy at statistically powered scale. The current five-patient Early Feasibility Study is designed to establish safety signals that inform Pivotal Trial design. PMA approval for a total artificial heart requires extensive durability testing, biocompatibility testing, and electromagnetic compatibility testing. Bridge-to-transplant is a more limited initial approval than destination therapy, which requires longer durability evidence. Australian TGA approval could precede U.S. PMA by several years.
Go-to-market: BiVACOR’s initial commercial pathway is bridge-to-transplant for biventricular heart failure patients who are not LVAD candidates. Texas Heart Institute and Baylor St. Luke’s are the initial commercial implantation centers. The Australian MRFF partnership provides a parallel development pathway and potential first commercial approvals in Australia under the TGA regulatory framework. Pricing for a total artificial heart at commercial launch would be expected in the $100,000 to $200,000 range per implant, consistent with the established LVAD market.
GP Lens: The total artificial heart has been a goal of cardiovascular medicine for 60 years. The SynCardia device, which is the only FDA-approved total artificial heart, was developed in the 1980s and uses technology from that era. BiVACOR’s MAGLEV design is not an incremental improvement. It is an architectural replacement. The proof is in the clinical results: five patients implanted, five patients successfully bridged to transplant, study expanding. That is the outcome the regulatory pathway is designed to recognize, and it has been achieved on $22 million in total funding. For an investor who understands the FDA device pathway and the addressable market in biventricular heart failure, this is one of the clearest examples of a legitimate breakthrough technology trading at a discovery-stage price relative to its eventual commercial value.
Ochre Bio — Oxford, United Kingdom | Founded 2019
What they do: Ochre Bio is developing RNA therapies for chronic liver disease using a research platform built on a dataset of more than 1,000 diseased human livers from three continents, analyzed with spatial sequencing, single-cell sequencing, and advanced imaging. The company’s core innovation is its Liver ICU: facilities in the United States where discarded donor livers — unsuitable for transplant but viable for research — are maintained alive on perfusion machines for multiple days. This allows Ochre to test RNA drug candidates directly in human liver tissue before any human subject exposure, bypassing the specific translation failure that kills the majority of liver disease drugs in clinical trials: mice do not accurately model human liver biology, and most pharma companies have no alternative. Co-founders are Jack O’Meara (CEO) and Quin Wills, M.D., Ph.D. (CSO), an Oxford-trained physician-scientist.
Revenue: Pre-revenue. Human liver preclinical testing ongoing as the validation step for drug candidate selection.
Latest raise + backers: $30 million Series A in October 2022 from Khosla Ventures, Hermes-Epitek, Backed VC, LifeForce Capital, Selvedge, AixThera, LifeLink, and EIT Health, plus angel investors including Alice Zhang (CEO, Verge Genomics), Kristen Fortney (CEO, BioAge), and Marty Chavez (Chairman, Recursion Pharmaceuticals). Total raised approximately $35 million including seed. Khosla’s participation is through its life sciences investment practice, which operates distinctly from its AI and enterprise software investments. The majority of the syndicate consists of specialist and mission-focused investors, not broadly known institutional VCs.
IP: Ochre Bio holds proprietary rights over its RNA drug candidates and the Liver ICU preclinical testing platform, including the machine perfusion protocols for maintaining human livers in research conditions over multi-day periods. The spatial and single-cell sequencing dataset across 1,000-plus diseased human livers represents a genomic atlas of liver disease at a scale no pharmaceutical company has built for internal use. The RNA chemistry platform being built as a parallel track is designed to generate proprietary delivery and chemistry IP distinct from existing RNA therapeutic patents held primarily by Alnylam and Arrowhead. Target discovery IP from the genomic atlas represents additional patent estate as candidates advance.
Top customers: Pre-commercial. Research collaborations at BioLabs at NYU Langone. Clinical translation partnerships forming with pharmaceutical companies evaluating the Liver ICU platform for their own candidate testing.
Moat and defensibility: The Liver ICU platform requires simultaneously: regulatory relationships with organ procurement organizations, machine perfusion engineering expertise, institutional medical research infrastructure, and a liver disease genomic dataset. Ochre has spent five years and $35 million building all four. A pharmaceutical company seeking to replicate it would need equivalent time and institutional access regardless of capital. The specific translation failure it addresses — mouse-to-human prediction failure — is formally recognized as the primary cause of attrition in liver disease drug development. The platform that solves it is not a competitive product. It is a scientific necessity.
SWOT:
| Strengths | Weaknesses |
| Human liver preclinical testing platform is structurally superior to animal models for predicting clinical outcomes. 1,000-plus liver genomic atlas is proprietary and irreproducible on a compressed timeline. RNA medicine has established mechanism-level proof of concept through Alnylam and mRNA vaccines. Oxford academic pedigree and physician-scientist CSO. | RNA therapeutic development for chronic liver disease is a long pathway. $35M total raised is thin for a company building toward IND. Alnylam and other well-funded RNA companies are pursuing liver targets with significantly more capital. |
| Opportunities | Threats |
| Chronic liver disease is the third leading cause of premature death in the UK and a top 10 cause of death globally. GLP-1 agonists creating a new intersection between metabolic and liver disease that opens new therapeutic categories. Transplant supply shortage makes regenerative liver therapy an urgent unmet need. | A competitor with better-funded RNA chemistry could outpace Ochre on delivery optimization. Organ procurement regulatory changes could disrupt the Liver ICU tissue supply. Clinical trial failure in the first RNA candidate would be a material setback. |
Regulatory and compliance hurdles: Human tissue research at the Liver ICU scale requires compliance with U.S. HIPAA, HRSA organ procurement regulations, IRB oversight for any research involving human tissue, and FDA regulations governing testing of investigational compounds in ex vivo human tissue. An IND is required before any RNA candidate moves into human clinical trials. In the UK, MHRA oversight applies to any UK-based candidate development. EU clinical trials require EMA coordination and compliance with the EU Clinical Trials Regulation.
Go-to-market: Ochre Bio’s nearest-term commercial moment is the advancement of its first RNA drug candidate into an IND application and Phase 1 clinical trial. That milestone typically unlocks significant partnership interest from pharmaceutical companies who lack the specific liver disease target discovery infrastructure Ochre has built. The Liver ICU platform itself can be licensed to pharma partners who need human liver preclinical testing for their own pipeline candidates, creating a revenue stream independent of Ochre’s own drug pipeline.
GP Lens: The chronic liver disease field has one of the highest clinical trial failure rates in medicine, and the primary reason is known and documented: mouse liver biology does not predict human liver outcomes. Ochre Bio has built the one tool that could materially improve those odds — a system for testing drug candidates in real human liver tissue before any human subject is exposed. That is not a product feature. That is a platform capability that pharmaceutical companies have tried to build internally and mostly failed to operationalize at research scale. The question for Ochre is not whether the platform works. It is whether the RNA candidates it selects will perform in the clinic. That answer will be known within three years. The current implied valuation at $35 million raised does not yet reflect the potential value of either the drug pipeline or the platform itself.
CergenX — Cork, Ireland | Founded 2021
What they do: CergenX has developed Wave, an AI-powered EEG system that enables non-specialist clinicians to assess neonatal brain injury risk in 15 minutes without specialist interpretation training. EEG is the clinical gold standard for measuring brain activity in newborns, but its interpretation requires years of specialist training. Twenty percent of newborns globally require neurological assessment. Over 80% of hospitals globally cannot perform that assessment because they lack trained specialists. Wave addresses this gap directly: AI trained on one of the world’s largest neonatal EEG research databases converts raw waveform data into a clear clinical decision output that any NICU nurse or general pediatrician can act on without specialist consultation. CergenX is a spinout from University College Cork’s INFANT Centre, co-founded by Professor Geraldine Boylan — a world authority in neonatal EEG with decades of institutional research — alongside Jason Mowles (CEO) and Sean Griffin.
Revenue: Pre-commercial, pending FDA clearance.²
Latest raise + backers: €7.9 million total — €6.7 million from Ireland’s Disruptive Technologies Innovation Fund, a competitive government grant program, and €1.2 million from private investors. No equity VC involvement. The company’s IP and equity remain almost entirely intact at a stage where a U.S. Series A equivalent would typically have diluted the founders significantly. The DTIF grant was awarded to a CergenX-led consortium including UCC’s INFANT Centre, following a competitive national evaluation of the technology’s potential.
IP: Patents on the AI architecture and signal processing methodology underlying Wave’s automated EEG interpretation. The training dataset — hundreds of neonates from the INFANT Research Centre, one of the world’s largest institutional collections of neonatal EEG data with longitudinal clinical outcome documentation — represents a proprietary corpus that no new entrant can replicate without decades of equivalent clinical research. Professor Boylan built that dataset across her career. It is not available for purchase at any price.
Top customers: Pre-commercial. Clinical evaluation studies completed at Cork University Hospital, Galway University Hospital, Portiuncula Hospital, and St. Luke’s General Hospital in Kilkenny. International validation planned ahead of commercial launch.
Moat and defensibility: The FDA Breakthrough Device Designation, granted January 2025, formally establishes that the FDA has determined Wave offers more effective diagnosis of a serious condition than currently available alternatives. That determination is based on the agency’s independent review of the clinical evidence, not the company’s marketing. TAP acceptance — Wave is one of only 65 devices globally in the FDA’s Total Product Lifecycle Advisory Program — means the FDA is actively collaborating on the development pathway, which structurally accelerates clearance. Professor Boylan’s decades of neonatal EEG research are the training data. No capital compresses a 20-year dataset.
SWOT:
| Strengths | Weaknesses |
| FDA Breakthrough Device Designation — formal agency determination of unmet need. One of 65 devices globally in FDA’s TAP program. World’s leading neonatal EEG researcher as co-founder. Proprietary training dataset built over decades. Near-zero equity dilution on government-grant funding. | Pre-commercial, pending FDA clearance. CPT reimbursement code not yet established. Limited capital for commercial scale activities. No contracted revenue yet. |
| Opportunities | Threats |
| 20% of newborns globally need assessment that 80% of hospitals cannot provide — the access gap is the market. NICU expansion globally driven by improving premature infant survival rates. UK, EU, and Australian markets can be entered through local regulatory frameworks in parallel with U.S. clearance. | A larger medtech company with access to comparable neonatal training datasets could develop a competing system. CPT code delays could extend the pre-revenue period beyond current projections. |
Regulatory and compliance hurdles: FDA De Novo or 510(k) clearance for the neonatal brain monitoring indication is the primary pathway. Breakthrough Device Designation expedites but does not eliminate this process. CPT code establishment through the AMA Editorial Panel is required for U.S. reimbursement — a separate process from FDA clearance that requires clinical utility evidence and procedural standardization. CE Mark for EU and MHRA for UK can proceed in parallel with the U.S. pathway.
Go-to-market: NICU-equipped hospitals in Ireland, the UK, and the United States are the initial commercial channel. The 15-minute result time and non-specialist usability extends reach to community hospitals and regional medical centers that constitute the majority of global hospitals. Government health systems in Ireland, the UK, and Australia, which operate under centralized procurement models, provide accessible early commercial channels that do not require the full insurance reimbursement pathway to be established before first revenue.
GP Lens: €7.9 million — mostly a government grant — to reach FDA Breakthrough Device Designation and TAP program acceptance. One of only 65 devices in the FDA’s most collaborative development program. Co-founded by the world’s leading researcher in the exact clinical domain the device addresses. No equity VC in the cap table. Twenty percent of newborns globally need an assessment that 80% of hospitals cannot provide. That gap is not a niche problem. It is a global access crisis with no current solution at scale. The gap between what this company has achieved on €7.9 million and the institutional attention it has received is the definition of the opportunity this series is designed to identify.
² CergenX is pre-commercial with no contracted revenue, which is a genuine Filter 2 risk by the standards of my investment thesis. The investment case here is specifically the regulatory position ahead of commercial proof: FDA Breakthrough Device Designation is the strongest possible agency signal that this technology addresses a real unmet need, and TAP participation means the FDA is actively collaborating on the development timeline. The data moat — Professor Boylan’s decades of neonatal EEG research — cannot be replicated regardless of capital. I am noting the pre-commercial status explicitly because it belongs in the article, not in a footnote.
The companies featured across this series represent my personal watchlist and research interest. I have not personally invested in any of them, and nothing written here constitutes investment advice. The views expressed are my own.
